Pre-IPO QuantumPharm (PHIP Updates) - Some Points Worth the Attention
QuantumPharm's business model struggle to scale revenue solely through service fees. Profitability is a pain point for AI pharmaceutical companies....
Pre-IPO QuantumPharm - Good Stories May Not Be Backed up by Performance
It's hard for QuantumPharm to general large revenue scale in a short time due to the weakness in business model. So, high valuation is...
Pre-IPO InSilico Medicine - AI Pharmaceutical Is Immature; Valuation Expansion Relies on Imagination
AI can help with the efficiency problem, but it cannot subvert the basic outline of drug R&D process, which is very difficult, as at critical...
No more insights